EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Bayesian Ordered Lattice Design for Phase I Clinical Trials

Gi-Ming Wang, Curtis Tatsuoka

Statistics in Medicine · 2026

DOI: 10.1002/sim.70456 ↗

At a glance

Journal article in Statistics in Medicine, 2026. Written by Gi-Ming Wang and 1 co-authors. Institution: Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA. Major MEDLINE topics: Clinical Trials, Phase I as Topic, Research Design. Cited 1 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Science Foundation, NCI NIH HHS, National Cancer Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

We develop a new framework specifically for early Phase I clinical trials called Bayesian Ordered Lattice Design (BOLD). This study is motivated by two key factors. First, Phase I clinical trials typically involve relatively small sample sizes, which can make the use of prior information on dose‐limiting toxicity (DLT) rates highly significant. To address this challenge, the proposed Bayesian methodology incorporates prior information and posterior updating to guide dose selection, toxicity monitoring, early stopping, and identification of the maximum tolerable dose (MTD). Second, a natural ordering among toxicity probabilities across different dose levels can be utilized, with the idea being that analysis of dose‐level posterior probabilities can and should acquire insights from data obtained at other dose levels, by leveraging their order relationship. Our proposed approach employs straightforward dose‐level Bayesian specifications and relies on intuitive and clinically interpretable DLT rate posterior probabilities for decision‐making. Importantly, we show that it can often outperform popular methods in terms of accuracy in determining the MTD. This Bayesian approach is also computationally simple and avoids simulation.

Subjects

MeSH terms (MEDLINE)

Clinical Trials, Phase I as TopicResearch DesignBayes TheoremHumansMaximum Tolerated DoseDose-Response Relationship, DrugComputer SimulationModels, StatisticalSample Size

Author keywords

Bayesian designdose selectionearly Phase I clinical triallatticesmaximum tolerable doseorder

Authors and institutions

  • Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Epidemiology and Public Health, Division of Biostatistics and Bioinformatics, University of Maryland-Baltimore, Baltimore, Maryland, USA.

Funding

  • National Science Foundation
  • NCI NIH HHS
  • National Cancer Institute

Cite

APA

Wang, G. M., & Tatsuoka, C. (2026). Bayesian Ordered Lattice Design for Phase I Clinical Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70456

Vancouver

Wang GM, Tatsuoka C. Bayesian Ordered Lattice Design for Phase I Clinical Trials. Statistics in Medicine. 2026. doi:10.1002/sim.70456

BibTeX
@article{Wang2026,
  author = {Wang, Gi-Ming and Tatsuoka, Curtis},
  title = {Bayesian Ordered Lattice Design for Phase I Clinical Trials},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70456}
}
Start for free →